REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-06. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
== Impact == The American Society of Health-System Pharmacists (ASHP) reported that 323 "active medication shortages" were reported in January–March 2024. As a result of drug scarcity, many healthcare systems were forced to either ration out essential drugs, triage patients based on the severity of their condition and their need for the drug, or both. Most of the medications impacted by the shortage were generic, low-cost drugs with sterile injectable medications such as chemotherapy agents being the most impacted. Tornado damage to a pharmaceutical manufacturing plant responsible for a large amount of national injectable drug production exacerbated shortages.
In an incomplete elution, part of the analytes remain in the sorbent because the eluent used does not have a strong enough affinity. Many of the adsorbents/materials are the same as in chromatographic methods, but SPE is distinctive, with aims separate from chromatography, and so has a unique niche in modern chemical science.
"Precautionary measures in radiation protection use the generally accepted model that the risk of lung cancer increases uniformly (linearly) with radon concentration. This means that an increased risk of lung cancer does not only occur above a certain value, but that a guideline or limit value only adjusts the magnitude of the risk in a meaningful way to other existing risks. Achieving a guideline or limit therefore means taking a risk that is still (socially) acceptable. It therefore makes perfect sense to take simple measures to reduce radon levels, even if they are below the guideline values." In Austria, the Radon Protection Ordinance in its version of September 10, 2021 is currently in force, which also defines the radon protection areas and radon precautionary areas.
Protein chemical synthesis by native peptide ligation of unprotected peptide segments is an interesting complement and potential alternative to the use of living systems for producing proteins. The synthesis of proteins requires efficient native peptide ligation methods, which enable the chemoselective formation of a native peptide bond in aqueous solution between unprotected peptide segments. The most frequently used technique for synthesizing proteins is Native chemical ligation (NCL). However, alternatives are emerging, one of which is SEA Native Peptide Ligation.
Sources: en.wikipedia.org
== Prognosis == With treatment, the five-year survival rate is >80%, and fewer than 30% of affected individuals require long-term dialysis. A study performed in Australia and New Zealand demonstrated that in patients requiring renal replacement therapy (including dialysis), the median survival time is 5.93 years. Without treatment, virtually every affected person will die from either advanced kidney failure or lung hemorrhages.
Black Widow Games was a video game developer specializing in promotional mods for Quake and Half-Life 3D engines. They are best known for their They Hunger series. Prominent members included Neil Manke (game and level design), Einar Saukas (game design and coding), and Magnus Jansén (game consultant and sound engineer). The company business model is based on developing contract-work mods for the marketing campaigns of customer companies and products (such as the S.O.F. TV series from Rysher Entertainment and the movie Underworld from Sony Pictures), freely distributed for promotion.
=== Novel technologies === Tecemotide is based on novel technologies, which may raise new regulatory issues that could delay or complicate regulatory approval. Additionally, as of 2013, the FDA had approved for commercial sale in the United States only one active vaccine designed to stimulate an immune response against cancer. Consequently, there is limited precedent for the successful development or commercialization of products based on these technologies in this area.
{\displaystyle Q={\begin{pmatrix}{-(a\pi _{C}+b\pi _{G}+c\pi _{T})}&a\pi _{C}&b\pi _{G}&c\pi _{T}\\a\pi _{A}&{-(a\pi _{A}+d\pi _{G}+e\pi _{T})}&d\pi _{G}&e\pi _{T}\\b\pi _{A}&d\pi _{C}&{-(b\pi _{A}+d\pi _{C}+f\pi _{T})}&f\pi _{T}\\c\pi _{A}&e\pi _{C}&f\pi _{G}&{-(c\pi _{A}+e\pi _{C}+f\pi _{G})}\end{pmatrix}}}
Beyond their food quota, the occupiers seized several rice stockpiles and other private and public goods, and were accused of rapes, beatings, occupying private dwellings, and burning down others, resulting only in apologies or partial compensation. By contrast, Vietnamese crimes against the Chinese were fully investigated, to the extent of executions for some Vietnamese who attacked Chinese soldiers. While Chiang Kai-shek, Xiao Wen (Hsiao Wen) and the Kuomintang Chinese government were uninterested in occupying Vietnam beyond the allotted time period and involving itself in the war between the Viet Minh and the French, the Yunnan warlord Lu Han wanted to establish a Chinese trusteeship of Vietnam under the principles of the Atlantic Charter with the aim of eventually preparing Vietnam for independence. Ho Chi Minh sent a cable on 17 October 1945 to American President Harry S. Truman calling on him, Generalissimo Chiang Kai-shek, Premier Joseph Stalin and Prime Minister Clement Attlee to go to the United Nations against France and demand that they not be allowed to return to occupy Vietnam, accusing France of having sold out and cheated the Allies by surrendering Indochina to Japan. Ho Chi Minh blamed Dong Minh Hoi and VNDQQ for signing the agreement with France which allowed its soldiers to return to Vietnam. Chinese communist guerrilla leader Chu Chia-pi visited northern Vietnam multiple times in 1945 and helped the Viet Minh fight against the French from Yunnan. Chiang Kai-shek forced the contentious French and Việt Minh to come to terms in the Ho–Sainteny agreement.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.